Re: AIM Rule 26
August 16 2007 - 5:25AM
UK Regulatory
RNS Number:2177C
Lombard Medical Technologies PLC
16 August 2007
Lombard Medical Technologies PLC
(the "Company")
AIM Rule 26 Information
London, UK, 16 August 2007 - Lombard Medical Technologies PLC (AIM: LMT)
announces that the information required by AIM Rule 26 (company information
disclosure) is available on the Lombard Medical Technologies PLC website:
http://www.lombardmedical.com/page_2_col____168.aspx
Enquiries:
Lombard Medical Technologies PLC Tel: 01235 750 800
Rhod Jones, Company Secretary
Nomura Code Securities Limited Tel: 020 7776 1200
Richard Potts
Financial Dynamics Tel: 020 7831 3113
John Gilbert
Notes to editors
About Lombard Medical
Lombard Medical Technologies PLC is a medical devices group developing stent
grafts and other medical products for use in the treatment of vascular disease.
The Company's lead product, AorfixTM, is a stent graft for the treatment of
aortic aneurysms, a balloon-like enlargement of the aorta which, if untreated,
may rupture and cause death. Abdominal and thoracic aortic aneurysms are the
13th largest cause of death in the US and the market is estimated to be worth
approximately US$2 billion by 2010. AorfixTM is currently being commercialised
in the EU, with US clinical trials having commenced during 2006. The Company's
Polymer Coatings Division primarily develops polymer coatings for use in
drug-eluting stents and has a number of research collaborations developing novel
products for this $6bn market.
The Company, headquartered in Oxfordshire, with operations in Yorkshire,
Ayrshire and Boston, USA, employs over 90 people.
Further background on the Company can be found at www.lombardmedical.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCKQLBFDVBLBBZ
Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jul 2023 to Jul 2024